Immatics N.V. ( IMTX ) NASDAQ Capital Market

Cena: 6.2 ( 1.64% )

Aktualizacja 06-17 21:49
NASDAQ Capital Market
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 542
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 70%
Ilość akcji: 100 581 000
Debiut giełdowy: 2018-12-12
WWW: https://www.immatics.com
CEO: Dr. Harpreet Singh Ph.D.
Adres: Paul-Ehrlich-Strasse 15
Siedziba: 72076 Tübingen
ISIN: NL0015285941
Opis firmy:

Immatics N.V., firma biofarmaceutyczna na stadium klinicznym, koncentruje się na odkrywaniu i rozwoju immunoterapii opartych na receptorze komórek T (TCR) do leczenia raka w Stanach Zjednoczonych. Firma opracowuje ukierunkowane immunoterapie, koncentrując się na leczeniu guzów litych poprzez dwa odrębne metody leczenia, takie jak adopcyjne terapie komórkowe (ACT) i bispecifics TCR podobne do przeciwciał. Jego kandydaci na produkty aktengine znajdują się w badaniach klinicznych fazy I, które obejmują IMA201, które są skierowane do antygenu 4 lub 8 związanego z czerniakiem u pacjentów z guzami litymi; IMA202, który jest skierowany do antygenu związanego z czerniakiem 1 u pacjentów z różnymi guzami litymi, w tym płaskonabłonkowym raku płucnym i rakowi płuc i raka wątrobowokomórkowego; i IMA203, który jest celem preferencyjnie wyrażającym antygen w czerniak u dorosłych pacjentów z nawrotowymi i/lub opornymi na ogniotem guzów litych, a także IMA204, który jest w badaniach przedklinicznych, które są ukierunkowane na komórkę zrębu nowotworu. Kandydaci produktu Bispecifics firmy TCR, które są w badaniach przedklinicznych, obejmują IMA401, antygen jądra raka do leczenia guzów stałych; i IMA402 do leczenia guzów litych. Rozwija także IMA101 w leczeniu raka; i IMA301, allogeniczny kandydat na terapię komórkową. Firma ma strategiczną umowę o współpracy z GlaxoSmithKline Intelektual Revelop Development ograniczoną do opracowania nowych adopcyjnych terapii komórkowych ukierunkowanych na wiele wskazań raka; MD Anderson Cancer Center w celu opracowania wielu komórek T i TCR adopcyjnych terapii komórkowych; Celgene Switzerland LLC w celu opracowania nowych adopcyjnych terapii komórkowych ukierunkowanych na wiele nowotworów; i Genmab A/S w celu opracowania angażujących komórek T -Bispecific Immunoterapie ukierunkowane na wiele wskazań raka. Immatics N.V. ma siedzibę w Tübingen w Niemczech.

Wskaźniki finansowe
Kapitalizacja (USD) 753 610 000
Aktywa: 577 233 000
Cena: 6.2
Wskaźnik Altman Z-Score: 2.0
Umiarkowany (ryzyko bankructwa średnie)
Dywidenda: 0
P/E: -31.0
Ilość akcji w obrocie: 70%
Średni wolumen: 773 745
Ilość akcji 121 550 000
Wskaźniki finansowe
Przychody TTM 115 682 176
Zobowiązania: 194 707 000
Przedział 52 tyg.: 3.3 - 13.12
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: -0.2
P/E branży: 26.1
Beta: 0.776
Raport okresowy: 2025-08-11
WWW: https://www.immatics.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Harpreet Singh Ph.D. Chief Executive Officer, MD, Member of Management Board & Executive Director 901 123 1975
Dr. Toni Weinschenk Ph.D. Co-Founder & Chief Innovation Officer 0 1974
Mr. Edward A. Sturchio J.D. General Counsel & Secretary 0 1976
Mr. Ephraim Hofsäß M.Sc. Vice President of SEC Reporting & Accounting 0 0
Dr. Carsten Reinhardt M.D., Ph.D. Chief Development Officer 0 1967
Mr. Jordan Silverstein Head of Strategy 0 1980
Dr. Hans-Georg Rammensee Ph.D. Co-Founder & Member of the Scientific Advisory Board 0 0
Mr. Cedrik M. Britten M.D. Chief Medical Officer 0 1976
Mr. Arnd Christ MBA Chief Financial Officer 0 1966
Mr. Steffen Walter Ph.D. Chief Operations Officer 0 1977
Wiadomości dla Immatics N.V.
Tytuł Treść Źródło Aktualizacja Link
Immatics Announces First Quarter 2025 Financial Results and Business Update Houston, Texas and Tuebingen, Germany, May 13, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended March 31, 2025. globenewswire.com 2025-05-13 11:00:00 Czytaj oryginał (ang.)
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois. globenewswire.com 2025-04-23 14:00:00 Czytaj oryginał (ang.)
Immatics N.V.: Trading Below Cash, But Not Without Reason Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain. Financially, IMTX has a $540mn market cap and $628mn cash, but negative enterprise value due to early-stage data and long catalyst desert. Phase 3 trial for IMA203 will produce interim data in early 2026, with no clear topline data timeline, creating uncertainty. seekingalpha.com 2025-03-28 15:02:08 Czytaj oryginał (ang.)
Immatics Announces Full Year 2024 Financial Results and Business Update Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024. globenewswire.com 2025-03-27 09:00:00 Czytaj oryginał (ang.)
New Strong Buy Stocks for February 12th BOH, AUB, BHRB, IMTX and RH have been added to the Zacks Rank #1 (Strong Buy) List on February 12, 2025. zacks.com 2025-02-12 09:46:13 Czytaj oryginał (ang.)
New Strong Buy Stocks for January 9th AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024. zacks.com 2025-01-09 09:59:29 Czytaj oryginał (ang.)
Immatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock? Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2025-01-07 15:16:27 Czytaj oryginał (ang.)
What Makes Immatics (IMTX) a New Buy Stock Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2024-11-18 15:00:36 Czytaj oryginał (ang.)
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates Immatics (IMTX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.35 per share a year ago. zacks.com 2024-11-18 11:10:18 Czytaj oryginał (ang.)
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics globenewswire.com 2024-11-18 09:00:00 Czytaj oryginał (ang.)
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers globenewswire.com 2024-11-08 19:00:00 Czytaj oryginał (ang.)
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy? Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-11-05 13:05:37 Czytaj oryginał (ang.)
Immatics: A Promising TCR Pipeline Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation estimates suggest a potential stock price of ~$19.26 based on conservative revenue assumptions. seekingalpha.com 2024-10-12 01:11:57 Czytaj oryginał (ang.)
Immatics Announces Pricing of $150 Million Public Offering H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $150 million. The offering is expected to close on October 15, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,437,500 additional shares at the public offering price, less the underwriting discount. globenewswire.com 2024-10-11 00:50:00 Czytaj oryginał (ang.)
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday? On Thursday, Immatics N.V.  IMTX stock is trading lower after the company commenced an underwritten public offering of $150 million. benzinga.com 2024-10-10 17:33:31 Czytaj oryginał (ang.)
Immatics Announces Proposed $150 Million Public Offering Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the commencement of an underwritten public offering of its ordinary shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. globenewswire.com 2024-10-10 11:30:00 Czytaj oryginał (ang.)
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST globenewswire.com 2024-10-10 10:30:00 Czytaj oryginał (ang.)
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024. globenewswire.com 2024-10-04 13:00:00 Czytaj oryginał (ang.)
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update Houston, Texas and Tuebingen, Germany, September 16, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today presented the proof-of-concept clinical data for the first candidate of its next-generation, half-life extended TCR Bispecifics platform, TCER® IMA401 (MAGEA4/8), during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. globenewswire.com 2024-09-16 09:25:00 Czytaj oryginał (ang.)
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that updated clinical data on its lead cell therapy candidate, ACTengine® IMA203 targeting PRAME, will be presented at the 21st International Congress of the Society for Melanoma Research. globenewswire.com 2024-09-06 11:00:00 Czytaj oryginał (ang.)
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates Immatics (IMTX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.35 per share a year ago. zacks.com 2024-08-13 13:11:20 Czytaj oryginał (ang.)
Immatics Announces Second Quarter 2024 Financial Results and Business Update Houston, Texas and Tuebingen, Germany, August 13, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended June 30, 2024. globenewswire.com 2024-08-13 11:00:00 Czytaj oryginał (ang.)
Wall Street Analysts Predict a 54.95% Upside in Immatics (IMTX): Here's What You Should Know The consensus price target hints at a 55% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-07-22 15:00:39 Czytaj oryginał (ang.)
Here's Why 'Trend' Investors Would Love Betting on Immatics (IMTX) If you are looking for stocks that are well positioned to maintain their recent uptrend, Immatics (IMTX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. zacks.com 2024-07-22 13:51:00 Czytaj oryginał (ang.)
Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates Immatics (IMTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.28 per share a year ago. zacks.com 2024-05-14 13:16:07 Czytaj oryginał (ang.)
Immatics Announces First Quarter 2024 Financial Results and Business Update Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME globenewswire.com 2024-05-14 11:00:00 Czytaj oryginał (ang.)
Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case Immatics, a German biotech company, achieved its Nasdaq listing in 2020 through a merger with Arya Sciences Acquisition Corp, a SPAC sponsored by Perceptive Advisors. The company focuses on developing T-cell receptor-based immunotherapies for solid tumors with unmet medical needs. Immatics has partnerships with Bristol Myers Squibb, Moderna, and Editas, and is advancing multiple candidates in clinical studies. seekingalpha.com 2024-04-27 14:32:07 Czytaj oryginał (ang.)